NPPB and hydrops fetalis: However, when NT-proBNP and HFABP were combined in a multimarker strategy, the rate of CV death at the end of the follow-up was 46% in HF patients with both biomarkers below their median values (n=18), 69% in HF patients with only one of the biomarkers higher than the median value (n=18), and 88% in HF patients with both NT-proBNP and HFABP higher than their median values (n=24).